联合口服避孕药治疗育龄女性月经大出血

I.B. Manukhin, E.I. Manukhina, I.R. Safaryan, M.A. Ovakimyan
{"title":"联合口服避孕药治疗育龄女性月经大出血","authors":"I.B. Manukhin, E.I. Manukhina, I.R. Safaryan, M.A. Ovakimyan","doi":"10.32364/2618-8430-2023-6-3-6","DOIUrl":null,"url":null,"abstract":"Background: heavy menstrual bleeding (HMB) is one of the unsolved problems in gynecological practice. The frequency of HMB is exactly unknown, which can be most likely related to an individually perceived blood loss volume. Patients with HMB are at high risk of iron deficiency and anemia. The main problem remains the lack of a single treatment algorithm for the HMB in female patients of reproductive age. Medical specialists should actively and, at the same time, effectively solve this clinical problem. Aim: to evaluate the efficacy of combined oral contraceptive (COC) containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate in patients of reproductive age with HMB. Patients and Methods: the study involved 87 female patients aged 22–43 y.o. with complaints of HMB. After a complete clinical and laboratory examination, all patients were prescribed COC (0.03 mg ethinylestradiol and 2 mg chlormadinone acetate) for 6 months with subsequent efficacy evaluation. The following parameters were evaluated: menstruation duration, RBC, hemoglobin and ferritin count. Results: initially, hemoglobin count was 78.4±0.5 g /L, RBC count — 2.9×1012/L, and ferritin count — less than 29 mg/dL in the setting of normal hemoglobin count were observed in 31 (35.6%) female patients. COCs prescription demonstrated efficacy in blood loss volume decrease during menstruation, which was noted by 85 (97.7%) female patients. Thus, it contributed to the iron content normalization in 29 (93.5%) of 31 patients. The frequency of side effects, which were manifested by discomfort in the mammary glands, nausea, headache, did not exceed 17%. All manifestations associated with drug intake did not require its cancellation or additional treatment. Conclusion: COC containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate is an effective drug for the treatment of HMB in female patients of reproductive age, allowing to reduce the frequency of latent iron deficiency forms. KEYWORDS: combined oral contraceptives, heavy menstrual bleeding, ethinylestradiol, chlormadinone acetate, iron deficiency anemia, menstrual cycle control, hormonal contraception. FOR CITATION: Manukhin I.B., Manukhina E.I., Safaryan I.R., Ovakimyan M.A. Combined oral contraceptives as a treatment method for female patients of reproductive age with heavy menstrual bleeding. Russian Journal of Woman and Child Health. 2023;6(3):253–257 (in Russ.). DOI: 10.32364/2618-8430-2023-6-3-6.","PeriodicalId":34075,"journal":{"name":"RMZh Mat'' i ditia","volume":"107 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combined oral contraceptives as a treatment method for female patients of reproductive age with heavy menstrual bleeding\",\"authors\":\"I.B. Manukhin, E.I. Manukhina, I.R. Safaryan, M.A. Ovakimyan\",\"doi\":\"10.32364/2618-8430-2023-6-3-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: heavy menstrual bleeding (HMB) is one of the unsolved problems in gynecological practice. The frequency of HMB is exactly unknown, which can be most likely related to an individually perceived blood loss volume. Patients with HMB are at high risk of iron deficiency and anemia. The main problem remains the lack of a single treatment algorithm for the HMB in female patients of reproductive age. Medical specialists should actively and, at the same time, effectively solve this clinical problem. Aim: to evaluate the efficacy of combined oral contraceptive (COC) containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate in patients of reproductive age with HMB. Patients and Methods: the study involved 87 female patients aged 22–43 y.o. with complaints of HMB. After a complete clinical and laboratory examination, all patients were prescribed COC (0.03 mg ethinylestradiol and 2 mg chlormadinone acetate) for 6 months with subsequent efficacy evaluation. The following parameters were evaluated: menstruation duration, RBC, hemoglobin and ferritin count. Results: initially, hemoglobin count was 78.4±0.5 g /L, RBC count — 2.9×1012/L, and ferritin count — less than 29 mg/dL in the setting of normal hemoglobin count were observed in 31 (35.6%) female patients. COCs prescription demonstrated efficacy in blood loss volume decrease during menstruation, which was noted by 85 (97.7%) female patients. Thus, it contributed to the iron content normalization in 29 (93.5%) of 31 patients. The frequency of side effects, which were manifested by discomfort in the mammary glands, nausea, headache, did not exceed 17%. All manifestations associated with drug intake did not require its cancellation or additional treatment. Conclusion: COC containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate is an effective drug for the treatment of HMB in female patients of reproductive age, allowing to reduce the frequency of latent iron deficiency forms. KEYWORDS: combined oral contraceptives, heavy menstrual bleeding, ethinylestradiol, chlormadinone acetate, iron deficiency anemia, menstrual cycle control, hormonal contraception. FOR CITATION: Manukhin I.B., Manukhina E.I., Safaryan I.R., Ovakimyan M.A. Combined oral contraceptives as a treatment method for female patients of reproductive age with heavy menstrual bleeding. Russian Journal of Woman and Child Health. 2023;6(3):253–257 (in Russ.). DOI: 10.32364/2618-8430-2023-6-3-6.\",\"PeriodicalId\":34075,\"journal\":{\"name\":\"RMZh Mat'' i ditia\",\"volume\":\"107 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RMZh Mat'' i ditia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32364/2618-8430-2023-6-3-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMZh Mat'' i ditia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2618-8430-2023-6-3-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:月经过多是妇科实践中尚未解决的问题之一。HMB的频率是完全未知的,这很可能与个人感知的失血量有关。HMB患者是缺铁和贫血的高危人群。主要问题仍然是对育龄女性患者的HMB缺乏单一的治疗算法。医学专家应积极主动,同时有效解决这一临床问题。目的:评价0.03 mg炔雌醇与2mg醋酸氯麦地酮联合口服避孕药对育龄HMB患者的疗效。患者和方法:研究纳入了87例22-43岁的女性HMB主诉患者。在完成临床和实验室检查后,所有患者均给予COC (0.03 mg炔雌醇和2mg醋酸氯麦地那酮)治疗6个月,并进行疗效评估。评估以下参数:月经持续时间、红细胞、血红蛋白和铁蛋白计数。结果:31例(35.6%)女性患者在血红蛋白计数正常的情况下,初始血红蛋白计数为78.4±0.5 g/ L,红细胞计数- 2.9×1012/L,铁蛋白计数-小于29 mg/dL。COCs处方对减少月经期间的失血量有疗效,85例(97.7%)女性患者注意到。因此,31例患者中有29例(93.5%)铁含量恢复正常。以乳腺不适、恶心、头痛为表现的副作用发生率不超过17%。所有与药物摄入相关的表现不需要取消或额外的治疗。结论:COC中含有0.03 mg炔雌醇和2mg醋酸氯麦地那酮是治疗育龄女性HMB的有效药物,可减少潜在缺铁形式的发生频率。关键词:联合口服避孕药,月经大出血,炔雌醇,醋酸氯麦地那酮,缺铁性贫血,月经周期控制,激素避孕。引文:Manukhin i.b., Manukhina e.e., Safaryan i.r., Ovakimyan M.A.联合口服避孕药作为育龄女性月经大出血患者的治疗方法。俄罗斯妇女与儿童健康杂志。2023;6(3):253-257。DOI: 10.32364 / 2618-8430-2023-6-3-6。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Combined oral contraceptives as a treatment method for female patients of reproductive age with heavy menstrual bleeding
Background: heavy menstrual bleeding (HMB) is one of the unsolved problems in gynecological practice. The frequency of HMB is exactly unknown, which can be most likely related to an individually perceived blood loss volume. Patients with HMB are at high risk of iron deficiency and anemia. The main problem remains the lack of a single treatment algorithm for the HMB in female patients of reproductive age. Medical specialists should actively and, at the same time, effectively solve this clinical problem. Aim: to evaluate the efficacy of combined oral contraceptive (COC) containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate in patients of reproductive age with HMB. Patients and Methods: the study involved 87 female patients aged 22–43 y.o. with complaints of HMB. After a complete clinical and laboratory examination, all patients were prescribed COC (0.03 mg ethinylestradiol and 2 mg chlormadinone acetate) for 6 months with subsequent efficacy evaluation. The following parameters were evaluated: menstruation duration, RBC, hemoglobin and ferritin count. Results: initially, hemoglobin count was 78.4±0.5 g /L, RBC count — 2.9×1012/L, and ferritin count — less than 29 mg/dL in the setting of normal hemoglobin count were observed in 31 (35.6%) female patients. COCs prescription demonstrated efficacy in blood loss volume decrease during menstruation, which was noted by 85 (97.7%) female patients. Thus, it contributed to the iron content normalization in 29 (93.5%) of 31 patients. The frequency of side effects, which were manifested by discomfort in the mammary glands, nausea, headache, did not exceed 17%. All manifestations associated with drug intake did not require its cancellation or additional treatment. Conclusion: COC containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate is an effective drug for the treatment of HMB in female patients of reproductive age, allowing to reduce the frequency of latent iron deficiency forms. KEYWORDS: combined oral contraceptives, heavy menstrual bleeding, ethinylestradiol, chlormadinone acetate, iron deficiency anemia, menstrual cycle control, hormonal contraception. FOR CITATION: Manukhin I.B., Manukhina E.I., Safaryan I.R., Ovakimyan M.A. Combined oral contraceptives as a treatment method for female patients of reproductive age with heavy menstrual bleeding. Russian Journal of Woman and Child Health. 2023;6(3):253–257 (in Russ.). DOI: 10.32364/2618-8430-2023-6-3-6.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
14
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信